APLS vs. LNTH
APLS (Apellis Pharmaceuticals, Inc.) and LNTH (Lantheus Holdings, Inc.) are both stocks. Both are in the Healthcare sector — APLS in Biotechnology, LNTH in Diagnostics & Research. Over the past 5 years, APLS returned -1.50%/yr vs 32.45%/yr for LNTH. At a 0.25 correlation, their price movements are largely independent.
Performance
APLS vs. LNTH - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, APLS achieves a 63.34% return, which is significantly higher than LNTH's 50.64% return.
APLS
- 1D
- 0.00%
- 1M
- 0.15%
- YTD
- 63.34%
- 6M
- 93.08%
- 1Y
- 118.01%
- 3Y*
- -22.49%
- 5Y*
- -1.50%
- 10Y*
- —
LNTH
- 1D
- 4.10%
- 1M
- 14.21%
- YTD
- 50.64%
- 6M
- 67.73%
- 1Y
- 29.04%
- 3Y*
- 4.18%
- 5Y*
- 32.45%
- 10Y*
- 46.44%
APLS vs. LNTH - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
APLS Apellis Pharmaceuticals, Inc. | 63.34% | -21.28% | -46.69% | 15.76% | 9.37% | -17.34% | 86.81% | 132.15% | -39.22% | 54.67% |
LNTH Lantheus Holdings, Inc. | 50.64% | -25.61% | 44.29% | 21.66% | 76.39% | 114.16% | -34.23% | 31.05% | -23.47% | -10.89% |
Correlation
The correlation between APLS and LNTH is 0.19, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.19 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.24 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.27 |
Correlation (All Time) Calculated using the full available price history since Nov 10, 2017 | 0.25 |
Fundamentals
APLS:
$1.41
LNTH:
$4.13
APLS:
29.10
LNTH:
24.26
APLS:
3.77
LNTH:
4.38
APLS:
$1.03B
LNTH:
$1.55B
APLS:
$920.13M
LNTH:
$935.17M
APLS:
$176.85M
LNTH:
$369.99M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
APLS vs. LNTH — Risk / Return Rank
APLS
LNTH
APLS vs. LNTH - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Apellis Pharmaceuticals, Inc. (APLS) and Lantheus Holdings, Inc. (LNTH). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| APLS | LNTH | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.99 | 0.62 | +0.37 |
Sortino ratioReturn per unit of downside risk | 3.67 | 1.03 | +2.64 |
Omega ratioGain probability vs. loss probability | 1.58 | 1.17 | +0.41 |
Calmar ratioReturn relative to maximum drawdown | 3.37 | 0.73 | +2.64 |
Martin ratioReturn relative to average drawdown | 7.45 | 1.28 | +6.17 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| APLS | LNTH | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.99 | 0.62 | +0.37 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.02 | 0.57 | -0.59 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | 0.75 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.16 | 0.43 | -0.27 |
Drawdowns
APLS vs. LNTH - Drawdown Comparison
The maximum APLS drawdown since its inception was -82.47%, roughly equal to the maximum LNTH drawdown of -78.62%. Use the drawdown chart below to compare losses from any high point for APLS and LNTH.
Loading charts...
Drawdown Indicators
| APLS | LNTH | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -82.47% | -78.62% | -3.85% |
Max Drawdown (1Y)Largest decline over 1 year | -43.53% | -40.22% | -3.31% |
Max Drawdown (3Y)Largest decline over 3 years | -82.47% | -59.46% | -23.01% |
Max Drawdown (5Y)Largest decline over 5 years | -82.47% | -59.46% | -23.01% |
Max Drawdown (10Y)Largest decline over 10 years | — | -68.52% | — |
Current DrawdownCurrent decline from peak | -56.03% | -18.90% | -37.13% |
Average DrawdownAverage peak-to-trough decline | -37.13% | -28.23% | -8.90% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 19.63% | 22.79% | -3.16% |
Volatility
APLS vs. LNTH - Volatility Comparison
The current volatility for Apellis Pharmaceuticals, Inc. (APLS) is 0.54%, while Lantheus Holdings, Inc. (LNTH) has a volatility of 13.28%. This indicates that APLS experiences smaller price fluctuations and is considered to be less risky than LNTH based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| APLS | LNTH | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 0.54% | 13.28% | -12.74% |
Volatility (6M)Calculated over the trailing 6-month period | 91.44% | 25.02% | +66.42% |
Volatility (1Y)Calculated over the trailing 1-year period | 147.98% | 47.26% | +100.72% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 91.01% | 56.89% | +34.12% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 83.60% | 61.96% | +21.64% |
Dividends
APLS vs. LNTH - Dividend Comparison
Neither APLS nor LNTH has paid dividends to shareholders.
Financials
APLS vs. LNTH - Financials Comparison
This section allows you to compare key financial metrics between Apellis Pharmaceuticals, Inc. and Lantheus Holdings, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
APLS vs. LNTH - Profitability Comparison
APLS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Apellis Pharmaceuticals, Inc. reported a gross profit of 151.46M and revenue of 192.01M. Therefore, the gross margin over that period was 78.9%.
LNTH - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Lantheus Holdings, Inc. reported a gross profit of 230.92M and revenue of 377.33M. Therefore, the gross margin over that period was 61.2%.
APLS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Apellis Pharmaceuticals, Inc. reported an operating income of 26.47M and revenue of 192.01M, resulting in an operating margin of 13.8%.
LNTH - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Lantheus Holdings, Inc. reported an operating income of 81.33M and revenue of 377.33M, resulting in an operating margin of 21.6%.
APLS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Apellis Pharmaceuticals, Inc. reported a net income of 18.66M and revenue of 192.01M, resulting in a net margin of 9.7%.
LNTH - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Lantheus Holdings, Inc. reported a net income of 118.42M and revenue of 377.33M, resulting in a net margin of 31.4%.
Frequently Asked Questions
APLS and LNTH have a correlation of 0.19, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
LNTH has higher volatility (13.28%) compared to APLS (0.54%). In terms of maximum drawdown, APLS dropped -82.47% vs LNTH's -78.62%.
APLS currently has the higher Sharpe Ratio (0.99 vs 0.62), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for APLS and LNTH
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer